RESEARCH PAPERS

Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X₇
V Bandara, J Foeng, B Gundsambuu, T Norton, S Napoli, D McPeake, T Tyllis, E Rohani-Rad, C Abbott, S Mills, L Tan, E Thompson, V Willet, V Nikitaras, J Zheng, I Comerford, A Johnson, J Coombs, M Oehler, C Ricciardelli, A Cowin, C Bonder, M Jensen, T Sadlon, S McColl, S Barry; nature communications 14, 5546 (2023)

ATP in the tumour microenvironment drives expression of nfP2X₇, a key mediator of cancer cell survival
SM Gilbert, CJ Oliphant, S. Hassan, AL Peille, P. Bronsert, S. Falzoni, F. Di Virgilio, S. McNulty, R. Lara

A phase I clinical trial demonstrates that nfP2X7-targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma
S.M. Gilbert, A. Gidley Baird, S. Glazer,  J.A. Barden,  A. Glazer , L.C. Teh, J. King

Markers for the development of early prostate cancer
Slater MD, Lauer C, Gidley-Baird A, Barden JA; J Pathol 2003- 199, 368-377

Increased Expression of apoptotic markers in melanoma
Slater M, Scolyer RA, Gidley-Baird A, Thompson JF, Barden JA; Melanoma Research 2003, 13-137 – 145

Genetic Polymorphisms of the Human P2X7 Receptor and Relationship to Function
Wiley JS, Gu BJ, Zhang W, Worthington RA, Dao-Ung P, Shemon AN, Sluyter R, Liang S, Barden JA

Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors
Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA; Histopathology 2004, 44, 206-215

Differentiation between cancerous and normal hyperplastic lobules in breast lesions
Slater M, Danieletto S, Pooley M, Teh LC, Gidley-Baird A, Barden JA; Breast Cancer Research & Treatment 83- 1-10, 2004

Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers
Slater M, Barden JA; Histopathology 2005, 47, 170-178

Detection of preneoplasia in histologically normal prostate biopsies
Slater MD, Delprado WJ, Murphy CR, Barden JA; Prostate Cancer Prostatic Dis. 2001, 4(2) 92-96

An Ile-568 to Asn Polymorphism Prevents Normal Trafficking and Function to the Human P2X7 Receptor
Wiley JS, Dao-Ung LP, Li C, Semon AN, Gu BJ, Smart ML, Fuller SJ, Barden JA, Petrou S, Sluyter R

Non-Functional P2X₇: A Novel and Ubiquitous Target in Human Cancer
Julian A. Barden, Aysen Yuksel, John Pedersen, Suzanne Danieletto, Warick Delprado; J Clin Cell Immunol 2014, 5:4

Therapeutic Targeting of the Cancer-Specific Cell Surface Biomarker nfP2X₇
Julian A Barden, Angus Gidley-Baird1, Liew Cheng Teh, G-Halli Rajasekariah, John Pedersen, Neil I Christensen, Derek Spielman, David M Ashley; J Clin Cell Immunol 2016, 7:3